Navigation Links
Osteotech Renews Tissue Recovery Agreement with the Euro Atlantic Transplant Alliance
Date:4/18/2008

EATONTOWN, N.J., April 18 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative medicine, announced today that it has renewed its exclusive tissue recovery agreement with The Euro Atlantic Transplant Alliance ("EATA"), a Bulgarian public non-profit foundation. The agreement, which was effective April 1, 2008, is for an initial term of seven years and automatically renews for successive four year terms unless a written notice of intent to terminate is provided by either party at least twelve months prior to the end of the initial, or any renewal term. This new agreement replaces a previous agreement that was due to expire in early 2009.

Sam Owusu-Akyaw, President and Chief Executive Officer of Osteotech, stated, "We are very pleased to renew our relationship with the Republic of Bulgaria and the EATA. Through the tissue recovery efforts of both organizations over the past five years, Osteotech has been able to use its processing and product technologies to bring safe and clinically effective OsteoBiologic products to the European market for use by surgeons to alleviate pain, promote biologic healing and restore function."

Dr. Roman A. Hitchev, President and Chief Medical Officer of TB Osteocentre Bulgaria EAD, an indirect wholly-owned subsidiary of Osteotech, commented, "We have had an excellent working relationship with the EATA over the last five years and together have established a successful tissue recovery system in the Republic of Bulgaria. We look forward to continuing our outstanding relationship with the EATA and, working with the EATA, to successfully integrate the Bulgarian tissue recovery and transplantation system into the tissue exchange system of the European Union."

Dr. Galina V. Balabanova, M.D., Executive Director of the EATA, remarked, "Osteotech and Osteocentre Bulgaria have been excellent partners and supporters of tissue banking in Bulgaria. They have a rich tradition in technological advancement and quality. Osteotech is also a key financial supporter of the collaboration we have with the Scoliosis Research Society, which allows us to provide pediatric spinal deformity surgery for children without healthcare insurance coverage."

The EATA, a public non-profit foundation authorized under the Bulgarian Transplant Law of 2007 and organized under the Bulgarian Public Foundations Law of 2001, is responsible for funding healthcare projects in Bulgaria for the public benefit, tissue transplantation, international patient referral services and pediatric spinal deformity surgery for children without healthcare insurance coverage. The EATA also provides financial management and fundraising to hospitals and providers participating in the Bulgarian national donor recovery network.

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech, this press release or the conference call, please go to Osteotech's website at http://www.osteotech.com.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements (as such are defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of April 18, 2008 and the Company does not intend to update this information.


'/>"/>
SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Osteotech Announces First Quarter Earnings Release and Conference Call Schedule
2. U.S. Patent Office Confirms Validity of Osteotechs U.S. Patent No. 5,676,146
3. Osteotech to Present at the Sidoti Conference in New York
4. Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
5. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
6. Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
7. Osteotech Announces Fourth Quarter and Full Year Earnings Release and Conference Call Schedule
8. Osteotech to Present at Sidoti Conference in San Francisco
9. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
10. Biomaxx Systems Inc. Renews Membership With Bioenergy Australia
11. Starion Achieves Worldwide Distribution of Proprietary Tissue Welding Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 18, 2017 , ... The ... (NIH) to update its Data Sharing Policy. Specifically, the nation’s leading informatics experts, ... subject to the existing policy. AMIA recommended that NIH earmark funding for researchers ...
(Date:1/19/2017)... NEW YORK , Jan. 18, 2017 /PRNewswire/ ... expected to reach USD 92.9 billion by 2025, ... Research, Inc. Pharmaceutical industry has been adaptive of ... functions as early as 2002. Among the services ... the forerunners. For instance, Johnson & Johnson was ...
(Date:1/18/2017)... ... January 18, 2017 , ... Opal ... using USB or PCI Express, announced the ZEM5310 USB 3.0 FPGA Module, combining ... a compact business-card sized form factor suitable for prototyping, testing, and production-ready integration. ...
(Date:1/18/2017)... Jan. 18, 2017   Parent Project Muscular Dystrophy ... end Duchenne muscular dystrophy (Duchenne) , today announced ... Jersey Institute of Technology (NJIT) and Talem Technologies (Talem) ... robotic technology to assist people living with Duchenne. ... technology – an embedded computer, software, a force sensor ...
Breaking Biology Technology:
(Date:1/6/2017)... JOLLA, Calif. , Jan. 6, 2017 /PRNewswire/ ... 1 safety studies in healthy volunteers of a ... intended to treat acute pancreatitis. ... is typically a mild disorder, but can be ... organ failure and sepsis, where extended hospital stays, ...
(Date:1/4/2017)... VEGAS , Jan. 4, 2017  For the thousands of attendees ... a global leader in connected health and biometric measurement devices and services, ... monitors. On display in A&D Medical,s special CES Exhibit ... represent the ongoing expansion of the company,s WellnessConnected product platform.  ... ...
(Date:12/22/2016)...  As part of its longstanding mission to improve genetic ... recently released its latest children,s book, titled The ... the topics of inheritance and variation of traits that are ... elementary school classrooms in the US. The ... Ariana Killoran , whose previous book with 23andMe, ...
Breaking Biology News(10 mins):